Top

Current Neurology and Neuroscience Reports

Published in:

Open Access 01-04-2021 | Hypotension | Autonomic Dysfunction (L.H. Weimer, Section Editor)

Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension

Authors: Stuart H. Isaacson, Khashayar Dashtipour, Ali A. Mehdirad, Amanda C. Peltier

Published in: Current Neurology and Neuroscience Reports | Issue 4/2021

Abstract

Purpose of Review

In autonomic failure, neurogenic orthostatic hypotension (nOH) and neurogenic supine hypertension (nSH) are interrelated conditions characterized by postural blood pressure (BP) dysregulation. nOH results in a sustained BP drop upon standing, which can lead to symptoms that include lightheadedness, orthostatic dizziness, presyncope, and syncope. nSH is characterized by elevated BP when supine and, although often asymptomatic, may increase long-term cardiovascular and cerebrovascular risk. This article reviews the pathophysiology and clinical characteristics of nOH and nSH, and describes the management of patients with both nOH and nSH.

Recent Findings

Pressor medications required to treat the symptoms of nOH also increase the risk of nSH. Because nOH and nSH are hemodynamically opposed, therapies to treat one condition may exacerbate the other. The management of patients with nOH who also have nSH can be challenging and requires an individualized approach to balance the short- and long-term risks associated with these conditions.

Summary

Approaches to manage neurogenic BP dysregulation include nonpharmacologic approaches and pharmacologic treatments. A stepwise treatment approach is presented to help guide neurologists in managing patients with both nOH and nSH.

1••.

Jordan J, Fanciulli A, Tank J, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens. 2019;37(8):1541–6. https://doi.org/10.1097/hjh.0000000000002078Scientific statement that summarizes the needs and challenges of managing and treating supine hypertension in patients who also have neurogenic orthostatic hypotension.CrossRefPubMed

Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72. https://doi.org/10.1007/s10286-011-0119-5.CrossRefPubMed

Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(11):1294–309. https://doi.org/10.1016/j.jacc.2018.05.079.CrossRefPubMed

Nwazue VC, Raj SR. Confounders of vasovagal syncope: orthostatic hypotension. Cardiol Clin. 2013;31(1):89–100.PubMedPubMedCentral

Celedonio JE, Arnold AC, Dupont WD, Ramirez CE, Diedrich A, Okamoto LE, et al. Residual sympathetic tone is associated with reduced insulin sensitivity in patients with autonomic failure. Clin Auton Res. 2015;25(5):309–15.PubMedPubMedCentral

6••.

Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28(4):355–62. https://doi.org/10.1007/s10286-018-0529-8Consensus statement that defines neurogenic supine hypertension and delineates its severity in patients with autonomic failure.CrossRefPubMedPubMedCentral

Novak V, Novak P, Spies JM, Low PA. Autoregulation of cerebral blood flow in orthostatic hypotension. Stroke. 1998;29(1):104–11. https://doi.org/10.1161/01.str.29.1.104.CrossRefPubMed

Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015;30(5):639–45. https://doi.org/10.1002/mds.26079.CrossRefPubMedPubMedCentral

Claassen DO, Adler CH, Hewitt LA, Gibbons C. Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. BMC Neurol. 2018;18(1):125. https://doi.org/10.1186/s12883-018-1129-x.CrossRefPubMedPubMedCentral

10.

Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology. 2017;88(1):17–24. https://doi.org/10.1212/wnl.0000000000003452.CrossRefPubMedPubMedCentral

11.

Stewart JM. Mechanisms of sympathetic regulation in orthostatic intolerance. J Appl Physiol (1985). 2012;113(10):1659–68. https://doi.org/10.1152/japplphysiol.00266.2012.CrossRef

12.

Palma JA, Redel-Traub G, Porciuncula A, Samaniego-Toro D, Lui YW, Norcliffe-Kaufmann L, et al. The impact of supine hypertension on target organ damage and mortality in patients with neurogenic orthostatic hypotension. Clin Auton Res. 2018;28:473.

13.

Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000;355(9205):725–6. https://doi.org/10.1016/S0140-6736(99)05320-9.

14.

Jordan J, Biaggioni I. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens (Greenwich). 2002;4(2):139–45.

15.

Biaggioni I. The pharmacology of autonomic failure: from hypotension to hypertension. Pharmacol Rev. 2017;69(1):53–62.PubMedPubMedCentral

16.

Lake CR, Ziegler MG, Kopin IJ. Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci. 1976;18(11):1315–25.PubMed

17.

Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension. 2003;42(2):136–42. https://doi.org/10.1161/01.hyp.0000081216.11623.c3.CrossRefPubMed

18.

Loavenbruck A, Sandroni P. Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions. Curr Med Res Opin. 2015;31(11):2095–104. https://doi.org/10.1185/03007995.2015.1087988.CrossRefPubMed

19.

Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139–46. https://doi.org/10.1161/CIRCULATIONAHA.108.805887.CrossRefPubMedPubMedCentral

20.

McDonell KE, Shibao CA, Claassen DO. Clinical relevance of orthostatic hypotension in neurodegenerative disease. Curr Neurol Neurosci Rep. 2015;15(12):78. https://doi.org/10.1007/s11910-015-0599-0.CrossRefPubMed

21.

Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018;33(3):349–58. https://doi.org/10.1002/mds.27186.CrossRefPubMed

22.

Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615–24. https://doi.org/10.1056/NEJMcp074189.CrossRefPubMed

23.

Arbique D, Cheek D, Welliver M, Vongpatanasin W. Management of neurogenic orthostatic hypotension. J Am Med Dir Assoc. 2014;15(4):234–9. https://doi.org/10.1016/j.jamda.2013.10.014.CrossRefPubMed

24.

Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, et al. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101(23):2710–5.PubMed

25.

Arnold AC, Okamoto LE, Gamboa A, Black BK, Raj SR, Elijovich F, et al. Mineralocorticoid receptor activation contributes to the supine hypertension of autonomic failure. Hypertension. 2016;67(2):424–9.PubMed

26.

Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567–82. https://doi.org/10.1007/s00415-016-8375-x.CrossRefPubMedPubMedCentral

27.

Garland EM, Gamboa A, Okamoto L, Raj SR, Black BK, Davis TL, et al. Renal impairment of pure autonomic failure. Hypertension. 2009;54(5):1057–61. https://doi.org/10.1161/HYPERTENSIONAHA.109.136853.CrossRefPubMedPubMedCentral

28.

Naschitz JE, Slobodin G, Elias N, Rosner I. The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Postgrad Med J. 2006;82(966):246–53.PubMedPubMedCentral

29.

Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci. 2011;310(1-2):123–8. https://doi.org/10.1016/j.jns.2011.06.047.CrossRefPubMedPubMedCentral

30.

Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938–48.PubMed

31.

Kaufmann H, Goldstein DS. Chapter 21–Autonomic dysfunction in Parkinson disease. Handb Clin Neurol. 2013;117:259–78. https://doi.org/10.1016/B978-0-444-53491-0.00021-3.

32.

Kaufmann H, Norcliffe-Kaufmann L, Palma JA, Biaggioni I, Low PA, Singer W, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81(2):287–97.PubMedPubMedCentral

33.

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14(7):710–9.PubMedPubMedCentral

34.

Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013;260(9):2212–9. https://doi.org/10.1007/s00415-012-6736-7.CrossRefPubMed

35.

Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–9.PubMedPubMedCentral

36.

Craig GM. Clinical presentation of orthostatic hypotension in the elderly. Postgrad Med J. 1994;70(827):638–42.PubMedPubMedCentral

37.

Shaw BH, Claydon VE. The relationship between orthostatic hypotension and falling in older adults. Clin Auton Res. 2014;24(1):3–13.PubMed

38.

François C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, et al. Six-month use of droxidopa for neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2019;6(3):235–42. https://doi.org/10.1002/mdc3.12726.CrossRefPubMedPubMedCentral

39.

Francois C, Biaggioni I, Shibao C, Ogbonnaya A, Shih HC, Farrelly E, et al. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson’s disease. J Med Econ. 2017;20(5):525–32. https://doi.org/10.1080/13696998.2017.1284668.CrossRefPubMed

40.

Merola A, Sawyer RP, Artusi CA, Suri R, Berndt Z, Lopez-Castellanos JR, et al. Orthostatic hypotension in Parkinson disease: impact on health care utilization. Parkinsonism Relat Disord. 2017;47:45–9. https://doi.org/10.1016/j.parkreldis.2017.11.344.CrossRefPubMed

41.

Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in synucleinopathies: a prospective cohort study. Neurology. 2015;85(18):1554–61.PubMedPubMedCentral

42.

Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, et al. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res. 2016;26(2):97–105. https://doi.org/10.1007/s10286-015-0336-4.CrossRefPubMed

43.

Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res. 2016;26(1):15–21. https://doi.org/10.1007/s10286-015-0324-8.CrossRefPubMed

44.

Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997;30(5):1062–7.PubMed

45.

Milazzo V, Maule S, Di Stefano C, Tosello F, Totaro S, Veglio F, et al. Cardiac organ damage and arterial stiffness in autonomic failure: comparison with essential hypertension. Hypertension. 2015;66(6):1168–75.PubMed

46.

Maule S, Milan A, Grosso T, Veglio F. Left ventricular hypertrophy in patients with autonomic failure. Am J Hypertens. 2006;19(10):1049–54. https://doi.org/10.1016/j.amjhyper.2006.02.016.CrossRefPubMed

47.

Cuspidi C, Sala C, Tadic M, Gherbesi E, De Giorgi A, Grassi G, et al. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: an updated review. J Clin Hypertens (Greenwich). 2017;19(7):713–21. https://doi.org/10.1111/jch.13023.CrossRef

48.

Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, Trenkwalder C. Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson's disease and multiple system atrophy. J Hypertens. 1998;16(10):1433–41.PubMed

49.

Okamoto LE, Gamboa A, Shibao C, Black BK, Diedrich A, Raj SR, et al. Nocturnal blood pressure dipping in the hypertension of autonomic failure. Hypertension. 2009;53(2):363–9.PubMed

50.

Kaufmann H, Norcliffe-Kaufmann L, Hewitt LA, Rowse GJ, White WB. Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. J Am Soc Hypertens. 2016;10(10):819–26. https://doi.org/10.1016/j.jash.2016.07.009.CrossRefPubMed

51•.

Di Stefano C, Sobrero G, Milazzo V, Vallelonga F, Romagnolo A, Zibetti M, et al. Cardiac organ damage in patients with Parkinson's disease and reverse dipping. J Hypertens. 2019. https://doi.org/10.1097/hjh.0000000000002249. A study that showed patients with Parkinson disease who also had nocturnal hypertension/reverse dipping had higher left ventricular mass and increased prevalence of left ventricle hypertrophy than nonreverse patients with Parkinson disease; the magnitude of the increase in left ventricular in reverse-dipping patients was similar to that measured in patients with essential hypertension.

52.

Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282(6):539–46.PubMed

53.

Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama Study. J Hypertens. 2002;20(11):2183–9.

54.

Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension. 2007;49(6):1235–41.PubMed

55.

Coleman CT, Stowasser M, Jenkins C, Marwick TH, Sharman JE. Central hemodynamics and cardiovascular risk in nondippers. J Clin Hypertens (Greenwich). 2011;13(8):557–62.

56.

Routledge FS, McFetridge-Durdle JA, Dean CR. Night-time blood pressure patterns and target organ damage: a review. Can J Cardiol. 2007;23(2):132–8.PubMedPubMedCentral

57.

Friedman O, Logan AG. Can nocturnal hypertension predict cardiovascular risk? Integr Blood Press Control. 2009;2:25–37.PubMedPubMedCentral

58.

Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169–76. https://doi.org/10.2147/VHRM.S53983.CrossRefPubMedPubMedCentral

59.

Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Ther. 2012;134(3):279–86. https://doi.org/10.1016/j.pharmthera.2011.05.009.CrossRefPubMed

60.

Northera® (droxidopa). Full Prescribing Information, Lundbeck NA Ltd, Deerfield, IL, 2017.

61.

Biaggioni I, Hewitt LA, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017;17(1):90. https://doi.org/10.1186/s12883-017-0867-5.CrossRefPubMedPubMedCentral

62.

ProAmatine® (midodrine hydrochloride). Full Prescribing Information, Shire US Inc., Lexington, MA, 2017.

63.

Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–51.PubMed

64.

Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48.PubMed

65.

Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120–4.PubMed

66.

Hamitouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B. Population pharmacokinetic-pharmacodynamic model of oral fludrocortisone and intravenous hydrocortisone in healthy volunteers. AAPS J. 2017;19(3):727–35. https://doi.org/10.1208/s12248-016-0041-9.CrossRefPubMed

67.

Schreglmann SR, Buchele F, Sommerauer M, Epprecht L, Kagi G, Hagele-Link S, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Eur J Neurol. 2017;24(4):545–51. https://doi.org/10.1111/ene.13260.CrossRefPubMed

68.

Hakamaki T, Rajala T, Lehtonen A. Ambulatory 24-h blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int J Clin Pharmacol Ther. 1998;36(7):367–9.PubMed

69.

Hussain RM, McIntosh SJ, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart. 1996;76(6):507–9.PubMedPubMedCentral

70.

Goldstein DS. L-dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006;24(3-4):189–203. https://doi.org/10.1111/j.1527-3466.2006.00189.x.CrossRefPubMed

71.

Drugs.com. Fludrocortisone FDA Professional Drug Information. https://www.drugs.com/pro/fludrocortisone.html. Accessed February 11 2020.

72.

Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724–8. https://doi.org/10.1161/01.CIR.0000083721.49847.D7.CrossRefPubMed

73.

Arnold AC, Ramirez CE, Choi L, Okamoto LE, Gamboa A, Diedrich A, et al. Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. Front Physiol. 2014;5:270. https://doi.org/10.3389/fphys.2014.00270.CrossRefPubMedPubMedCentral

74.

Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105(2):116–24.PubMed

75.

Parsaik AK, Singh B, Altayar O, Mascarenhas SS, Singh SK, Erwin PJ, et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013;28(11):1496–503. https://doi.org/10.1007/s11606-013-2520-3.CrossRefPubMedPubMedCentral

76•.

Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K. Standing and supine blood pressure outcomes associated with droxidopa and midodrine in patients with neurogenic orthostatic hypotension: a Bayesian meta-analysis and mixed treatment comparison of randomized trials. Ann Pharmacother. 2018;52(12):1182–94. https://doi.org/10.1177/1060028018786954A mixed-treatment meta-analysis showing that compared with placebo, the relative risk of supine hypertension was significantly higher for midodrine but not for droxidopa.

77.

Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604–10.PubMed

78.

Mestinon® (pyridostigmine bromide). Full Prescribing Information, ICN Pharmaceuticals, Costa Mesa, CA, 2001.

79.

Aquilonius SM, Eckernäs SA, Hartvig P, Lindström B, Osterman PO. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol. 1980;18(5):423–8. https://doi.org/10.1007/bf00636797.CrossRefPubMed

80.

Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74(9):1294–8.PubMedPubMedCentral

81.

Shibao C, Okamoto LE, Gamboa A, Yu C, Diedrich A, Raj SR, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847–51. https://doi.org/10.1161/HYPERTENSIONAHA.110.154898.CrossRefPubMedPubMedCentral

82.

Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513–8. https://doi.org/10.1001/archneur.63.4.noc50340.CrossRefPubMed

83.

Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Neurology. 2017;89(10):1078–86. https://doi.org/10.1212/wnl.0000000000004340.CrossRefPubMed

84.

Shibao C, Grijalva CG, Lipsitz LA, Biaggioni I, Griffin MR. Early discontinuation of treatment in patients with orthostatic hypotension. Auton Neurosci. 2013;177(2):291–6. https://doi.org/10.1016/j.autneu.2013.08.064.CrossRefPubMedPubMedCentral

85.

Campbell IW, Ewing DJ, Clarke BF. Therapeutic experience with fludrocortisone in diabetic postural hypotension. Br Med J. 1976;1(6014):872–4.PubMedPubMedCentral

86.

Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch Neurol. 1975;32(1):50–1.PubMed

87•.

Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298–308. https://doi.org/10.1002/mdc3.12478A review article describing the diagnosis and management of neurogenic orthostatic hypotension and providing a summary of key nonpharmacologic and pharmacologic approaches for the treatment of patients with neurogenic orthostatic hypotension.

88.

Kaufmann H, Biaggioni I. Chapter 63 - Disorders of the autonomic nervous system. In: Fillit HM, Rockwood K, Woodhouse K, editors. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. 7th ed. Philadelphia: W.B. Saunders; 2010. p. 498–510.

89.

Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension. 1992;19(6 Pt 1):567–74. https://doi.org/10.1161/01.hyp.19.6.567.CrossRefPubMed

90.

Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res. 2008;18(suppl 1):14–8. https://doi.org/10.1007/s10286-007-1003-1.CrossRefPubMed

91.

Handler J. Symptomatic orthostatic hypotension/supine hypertension. J Clin Hypertens (Greenwich). 2005;7(10):612–6. https://doi.org/10.1111/j.1524-6175.2005.04139.x.CrossRef

92.

Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015;30(5):646–54.PubMed

93.

Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328–35. https://doi.org/10.1212/WNL.0000000000000615.CrossRefPubMedPubMedCentral

94•.

Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc. 2017;6(10):e006848 A retrospective cohort study of patients with orthostatic hypotension showing that patients treated with fludrocortisone had a 20% greater risk of all-cause hospitalization compared with patients treated with midodrine and that those patients who also had congestive heart failure had even a greater risk (42%).

95.

Mazza A, Ravenni R, Antonini A, Casiglia E, Rubello D, Pauletto P. Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. Neurol Sci. 2013;34(5):621–7. https://doi.org/10.1007/s10072-012-1251-2.CrossRefPubMed

96.

Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med. 1992;232(2):139–45.PubMed

97.

Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996;98(4):894–8.PubMedPubMedCentral

98.

Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015;13(8):875–91. https://doi.org/10.1586/14779072.2015.1057504.CrossRefPubMedPubMedCentral

99.

Cozaar (losartan potassium). Full Prescribing Information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2018.

100.

Nitro-Dur (nitroglycerin patch). Full Prescribing Information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2014.

101.

Capoten (captopril). Full Prescribing Information. Spring Valley, NY: Par Pharmaceutical Companies, Inc.; 2012.

102.

Apresoline (hydralazine). Full prescribing information, Ciba-Geigy Corporation, Summit, NJ, 1995.

103.

Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, et al. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension. 2013;61(3):701–6. https://doi.org/10.1161/HYPERTENSIONAHA.111.00377.CrossRefPubMed

104.

Jordan J, Shannon JR, Pohar B, Paranjape SY, Robertson D, Robertson RM, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol. 1999;10(1):35–42.PubMed

105.

Procardia® (nifedipine capsule). Full prescribing information. New York, NY: Pfizer Inc; 2016.

106.

Inspra (eplerenone). Full Prescribing Information, Pfizer, New York, NY, USA, 2008.

107.

Baker J, Kimpinski K. Management of supine hypertension complicating neurogenic orthostatic hypotension. CNS Drugs. 2017;31(8):653–63.PubMed

108.

Young TM, Asahina M, Watson L, Mathias CJ. Hemodynamic effects of clonidine in two contrasting models of autonomic failure: multiple system atrophy and pure autonomic failure. Mov Disord. 2006;21(5):609–15. https://doi.org/10.1002/mds.20755.CrossRefPubMed

109.

Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47–53. https://doi.org/10.1161/HYPERTENSIONAHA.107.089961.CrossRefPubMed

110.

Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018;91(16):e1539–e44.PubMedPubMedCentral

Title: Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension
Authors: Stuart H. Isaacson
Khashayar Dashtipour
Ali A. Mehdirad
Amanda C. Peltier
Publication date: 01-04-2021
Publisher: Springer US
Keywords: Hypotension
Hypertension
Hypotension
Hypertension
Parkinson's Disease
Published in: Current Neurology and Neuroscience Reports / Issue 4/2021
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01104-3

At a glance: The STEP trials

Springer Medicine

Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2021

Challenges and Controversies in the Genetic Diagnosis of Hereditary Spastic Paraplegia

Telehealth in Multiple Sclerosis Clinical Care and Research

The Role of Genetic Testing for Parkinson’s Disease

Digital Technology in Movement Disorders: Updates, Applications, and Challenges